Objective
The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans.
We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma
Fields of science
- medical and health sciencesclinical medicinepneumologyasthma
- natural sciencesbiological sciencesmicrobiologybacteriology
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
10561 Athina
Greece
See on map
Participants (9)
M13 9PL Manchester
See on map
7270 Davos Platz
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
115 27 Athina
See on map
90419 Lodz
See on map
Participation ended
901 87 Umea
0160 Tbilisi
See on map
0160 Tbilisi
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1000 Bruxelles
See on map
153 44 Gerakas Attiki
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.